FS Reports最新文献

{"title":"The use of transvaginal ultrasound alters physiologic uterine peristalsis in gynecologic participants","authors":"Kelsey Anderson M.D. ,&nbsp;Sicheng Wang Ph.D. ,&nbsp;Stephanie Pizzella M.S. ,&nbsp;Qing Wang Ph.D. ,&nbsp;Yong Wang Ph.D. ,&nbsp;Valerie Ratts M.D.","doi":"10.1016/j.xfre.2024.06.004","DOIUrl":"10.1016/j.xfre.2024.06.004","url":null,"abstract":"<div><h3>Objective</h3><p>To study whether transvaginal ultrasound (TVUS) affected the uterine peristalsis (UP) patterns in nonpregnant participants.</p></div><div><h3>Design</h3><p>Institutional review board–approved, prospective observational cohort study. The noninvasive UP imaging (UPI) system uses electrode patches placed on the patient’s skin just above the pubic bone and on the low back to quantify the 3-dimensional electrical activation pattern during UP by calculating peristalsis frequency, duration, magnitude, and activation ratio. A 20-minute UPI scan was completed without TVUS followed by a 10-minute UPI scan acquired simultaneously during TVUS examination as a comparison.</p></div><div><h3>Setting</h3><p>University medical center.</p></div><div><h3>Patient(s)</h3><p>Twenty-eight participants with regular menstrual cycles not taking hormonal medication and with a normal uterus were included in analysis.</p></div><div><h3>Intervention(s)</h3><p>Subjects were imaged longitudinally during the four phases of the menstrual cycle (menses, proliferative, periovulatory, and secretory) with a UPI scan followed by concurrent TVUS and UPI scan. Serum hormone levels (estradiol and progesterone) and TVUS evaluating follicular development were obtained during each visit to confirm menstrual cycle phase.</p></div><div><h3>Main Outcome Measure(s)</h3><p>Duration, frequency, magnitude, and activation ratio of the UP waves.</p></div><div><h3>Result(s)</h3><p>With the use of simultaneous TVUS, UP waves had a change in at least one of the outcomes measured in all visits. The frequency, magnitude, and duration were significantly higher with TVUS use in all phases of the menstrual cycle. The activation ratio was higher with TVUS during all phases except the periovulatory phase.</p></div><div><h3>Conclusion(s)</h3><p>This study demonstrated that TVUS may inherently affect UP waves. Therefore, noninvasive technology may more accurately measure physiologic peristalsis waves.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 3","pages":"Pages 296-303"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000758/pdfft?md5=0fb1a4c84af711e95bcbb2195386d8fe&pid=1-s2.0-S2666334124000758-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142240966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of maternal factors in egg freezing cycles with in vitro fertilization outcomes of both in vivo and rescue in vitro matured oocytes","authors":"Terry Schlenker B.S. ,&nbsp;Ye Yuan Ph.D. ,&nbsp;Elizabeth A. Jannaman B.S. ,&nbsp;William B. Schoolcraft M.D. ,&nbsp;Jason E. Swain Ph.D.","doi":"10.1016/j.xfre.2024.06.005","DOIUrl":"10.1016/j.xfre.2024.06.005","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 3","pages":"Pages 333-337"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266633412400076X/pdfft?md5=3691abe4fcdbd31c49aa7e008abcbbe1&pid=1-s2.0-S266633412400076X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141702947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unexpected poor oocyte retrieval: the phenomenon of the borderline response to the gonadotropin-releasing hormone (GnRH) agonist trigger","authors":"Richard J. Paulson M.D., M.S.","doi":"10.1016/j.xfre.2024.08.001","DOIUrl":"10.1016/j.xfre.2024.08.001","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 3","pages":"Pages 229-230"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000825/pdfft?md5=39443019363727fef6aeb67aab9c58b3&pid=1-s2.0-S2666334124000825-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142240901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Office of Public Affairs update: a quarterly update from the American Society for Reproductive Medicine Office of Public Affairs on key developments in reproductive health policy","authors":"Rebecca O’Connor J.D.","doi":"10.1016/j.xfre.2024.08.002","DOIUrl":"10.1016/j.xfre.2024.08.002","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 3","pages":"Page 233"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000837/pdfft?md5=d455f0dd8a26f9a2c5aa0106695ca72b&pid=1-s2.0-S2666334124000837-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142240898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intracytoplasmic sperm injection versus conventional in vitro fertilization in unexplained infertility","authors":"Aya Iwamoto M.S., M.D. ,&nbsp;Karen M. Summers M.P.H. ,&nbsp;Amy Sparks Ph.D. ,&nbsp;Abigail C. Mancuso M.D.","doi":"10.1016/j.xfre.2024.06.003","DOIUrl":"10.1016/j.xfre.2024.06.003","url":null,"abstract":"<div><h3>Objective</h3><p>To compare cumulative live birth rate (CLBR) and cost-effectiveness of intracytoplasmic sperm injection (ICSI) vs. conventional in vitro fertilization (cIVF).</p></div><div><h3>Design</h3><p>Retrospective cohort study of cycles reported to the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System.</p></div><div><h3>Setting</h3><p>Society for Assisted Reproductive Technology (SART) member IVF clinics in the United States.</p></div><div><h3>Patient(s)</h3><p>Patients with unexplained infertility who underwent first autologous retrieval cycles between January 2017 and December 2019 with linked fresh and frozen embryo transfers through December 2021.</p></div><div><h3>Intervention(s)</h3><p>ICSI vs. cIVF.</p></div><div><h3>Main Outcome Measure(s)</h3><p>The primary outcome was CLBR, defined as ≤1 live birth from a retrieval cycle and all linked embryo transfers. Secondary outcomes included two pronuclear (2PN) per oocyte retrieved, miscarriage rate, and total number of transferred or frozen embryos per 2PN. Subsamples with and without preimplantation genetic testing for aneuploidy (PGT-A) were analyzed. Outcomes were adjusted for age, body mass index, number of oocytes retrieved, length of follow-up, and clinic ICSI use rate.</p></div><div><h3>Result(s)</h3><p>A total of 18,805 patients with unexplained infertility were included. No difference in CLBR was found among cycles without genetic testing (54.4% ICSI vs. 57.5% cIVF) and with PGT-A (47.6% ICSI vs. 51.8% cIVF). Intracytoplasmic sperm injection cycles without genetic testing had a higher miscarriage rate (16.4% vs. 14.4%) but no difference was seen in cycles with PGT-A (13.9% ICSI vs. 13.2% cIVF). Intracytoplasmic sperm injection cycles had a significantly lower ratio of 2PN per oocyte retrieved without genetic testing (59.7% vs. 60.9%) and with PGT-A (63.3% vs. 65.8%). The ratio of embryos transferred or frozen per 2PN was not significantly different in cycles without genetic testing (49.4% vs. 49.6%) or with PGT-A (54.2% vs. 55.2%). Total fertilization failure occurred in 216 patients (4%) who underwent cIVF and in 153 patients (1.1%) who used ICSI.</p><p>Compared with cIVF alone, an estimated additional $11,011,500 was charged to patients for ICSI without genetic testing and $9,010,500 was charged to patients for ICSI with PGT-A over 2 years by Society for Assisted Reproductive Technology clinics. On the basis of total fertilization failure rates, 35 patients would require treatment with routine ICSI to avoid a single cycle of total fertilization failure with cIVF.</p></div><div><h3>Conclusion(s)</h3><p>Routine use of ICSI in unexplained infertility is not warranted due to the additional cost and lack of CLBR benefit.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 3","pages":"Pages 263-271"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000746/pdfft?md5=4e1fb926bff87b6361e931652abfd536&pid=1-s2.0-S2666334124000746-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142240891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of demographic and clinical factors on elagolix plus add-back therapy effects on patient-reported nonbleeding symptoms in women with heavy menstrual bleeding and uterine fibroids: a post hoc analysis of data from two clinical trials","authors":"","doi":"10.1016/j.xfre.2024.06.002","DOIUrl":"10.1016/j.xfre.2024.06.002","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the efficacy of elagolix plus add-back therapy (estradiol [1 mg] and norethindrone acetate [0.5 mg] once daily) on patient-reported nonbleeding symptoms and menstrual bleeding associated with uterine fibroids (UFs) across different subpopulations.</p></div><div><h3>Design</h3><p>Post hoc analysis of two phase 3 clinical trials—Elaris UF-1 and UF-2.</p></div><div><h3>Setting</h3><p>A total of 76 (UF-1) and 77 (UF-2) US clinical sites.</p></div><div><h3>Patient(s)</h3><p>Women (N = 591) with UFs and heavy menstrual bleeding.</p></div><div><h3>Intervention(s)</h3><p>Elagolix (300 mg) twice daily with add-back therapy (the indicated dose for UF-associated heavy menstrual bleeding) vs. placebo for 6 months.</p></div><div><h3>Main Outcome Measure(s)</h3><p>“Very much improved” or “much improved” change in nonbleeding symptoms (abdominal/pelvic pain, abdominal/pelvic pressure/cramping, back pain, and abdominal bloating) and menstrual bleeding measured using a Patient Global Impression of Change scale. Improvements were assessed in subpopulations stratified using baseline characteristics (age, race [self-reported], body mass index, and International Federation of Gynecology and Obstetrics fibroid classification).</p></div><div><h3>Result(s)</h3><p>Across subpopulations, differences favored elagolix plus add-back therapy (vs. placebo) for most symptoms at month 1 and all symptoms at months 3 as well as 6. In patients with characteristics commonly associated with high disease burden (age &gt;40 years, Black/African American), those treated with elagolix plus add-back therapy reported significantly greater improvements vs. placebo at months 1–6 (<em>P</em>&lt;.05) for all nonbleeding and bleeding symptoms (<em>P</em>≤.05).</p></div><div><h3>Conclusion(s)</h3><p>Premenopausal women with heavy menstrual bleeding and UFs receiving elagolix plus add-back therapy experienced significant improvements in nonbleeding as well as bleeding symptoms from months 1–6, regardless of baseline characteristics.</p></div><div><h3>Clinical Trial Registration Number</h3><p>NCT02654054 and NCT02691494.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 3","pages":"Pages 285-295"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000734/pdfft?md5=cc38af74c44775138d3bc776b91f6de5&pid=1-s2.0-S2666334124000734-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141397269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Which obstetrics-gynecology residency programs are training future reproductive endocrinology and infertility fellows? An observational study","authors":"Zachary S. Anderson M.D. ,&nbsp;Erika P. New M.D. ,&nbsp;Aaron D. Masjedi M.D. ,&nbsp;M. Blake Evans D.O.","doi":"10.1016/j.xfre.2024.07.003","DOIUrl":"10.1016/j.xfre.2024.07.003","url":null,"abstract":"<div><h3>Objective</h3><p>To identify where reproductive endocrinology and infertility (REI) fellows trained for residency.</p></div><div><h3>Design</h3><p>Observational, cross-sectional study.</p></div><div><h3>Setting</h3><p>Not applicable.</p></div><div><h3>Subject(s)</h3><p>Reproductive endocrinology and infertility fellows.</p></div><div><h3>Intervention(s)</h3><p>Not applicable.</p></div><div><h3>Main Outcome Measure(s)</h3><p>Percentage of fellows who completed residency training at an institution with an REI fellowship program.</p></div><div><h3>Result(s)</h3><p>A total of 289 fellows were identified among the graduating fellowship classes from 2023–2027. Of those fellows, 69.9% completed residency at an institution that had an associated REI fellowship program, and 19.7% remained at the same institution for residency and fellowship. In the last 5 years, 34.4% of obstetrics and gynecology residency programs have had at least 1 resident enter REI fellowship.</p></div><div><h3>Conclusion(s)</h3><p>Most matriculated REI fellow physicians train at residency programs that have an associated REI fellowship program.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 3","pages":"Pages 259-262"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000801/pdfft?md5=09add9b4b973c7481ea8804553c4576b&pid=1-s2.0-S2666334124000801-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141850548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum progesterone concentration in frozen embryo transfer preparation: how (and if) we should measure it","authors":"Allison A. Eubanks M.D. ,&nbsp;Dominque de Ziegler M.D. ,&nbsp;Kate Devine M.D.","doi":"10.1016/j.xfre.2024.08.004","DOIUrl":"10.1016/j.xfre.2024.08.004","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 3","pages":"Pages 248-249"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000850/pdfft?md5=6213d972fcdf79142bff67f8c2389980&pid=1-s2.0-S2666334124000850-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142240965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transvaginal radiofrequency ablation: a therapeutic option for managing symptomatic uterine fibroids in women with reproductive desires","authors":"Ma Eugenia Marín Martínez M.D. ,&nbsp;Sara Cruz-Melguizo M.D., Ph.D. ,&nbsp;Gema Vaquero Argüello M.D. ,&nbsp;Virginia Engels Calvo M.D., Ph.D. ,&nbsp;Ma Luisa De la Cruz Conty Ph.D. ,&nbsp;Tirso Pérez Medina M.D., Ph.D.","doi":"10.1016/j.xfre.2024.07.001","DOIUrl":"10.1016/j.xfre.2024.07.001","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate whether transvaginal radiofrequency (RF) ablation of fibroids is a technique that can be offered to women with reproductive desires.</p></div><div><h3>Design</h3><p>Unicentric, prospective, observational study.</p></div><div><h3>Setting</h3><p>University Hospital.</p></div><div><h3>Patient(s)</h3><p>Twenty-seven individuals who desired to become mothers after undergoing RF ablation for symptomatic fibroids.</p></div><div><h3>Intervention(s)</h3><p>Transvaginal RF ablation for symptomatic fibroids with a maximum total volume of 145 cm³.</p></div><div><h3>Main Outcome Measure(s)</h3><p>The reduction in the size of the fibroids, improvement of symptoms, and reproductive outcomes during the 24 months after the ablation. For patients who achieved pregnancy, we assessed the type of conception, course of gestation, type of delivery, neonatal outcomes, and occurrence of both maternal and fetal complications.</p></div><div><h3>Result(s)</h3><p>A statistically significant reduction in symptoms related to the fibroids 6 months after the ablation was demonstrated through the implementation of the Symptom Severity Scale. No patient required hospitalization after the procedure, and on average from the third day after intervention, they resumed their work activities without the need for analgesics. Among those patients who attempted pregnancy during the 24-month follow-up period, 73.68 % (14/19) achieved motherhood. There were no cases of uterine rupture, premature birth, or intrauterine fetal death.</p></div><div><h3>Conclusion(s)</h3><p>Radiofrequency ablation for fibroids seems to be a promising, safe, and low-complexity alternative that does not appear to interfere with the development of a normal term gestation.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 3","pages":"Pages 320-327"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000783/pdfft?md5=90a85168e256639444f1170c5361da76&pid=1-s2.0-S2666334124000783-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141697177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reviewers of the Year 2023. F&S Reports celebrates excellence in our world class reviewers","authors":"","doi":"10.1016/j.xfre.2024.07.004","DOIUrl":"10.1016/j.xfre.2024.07.004","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 3","pages":"Pages 231-232"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000813/pdfft?md5=2b084e87a9d7f90d08e2b2b3212a65ae&pid=1-s2.0-S2666334124000813-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142240902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}